

# **Annual report and financial statements**

For the year ended 31 March 2019

**Charity registration number: 1140679** 

Company number: 7543237

## Annual report and financial statements Year ended 31 March 2019

CONTENTS	Page	
Trustees, reference and administrative details of the Charity	2	
Trustees report (incorporating the strategic report)	3	
Constitution	3	
Objects and activities	3	
Public benefit statement	3	
About Moorfields Eye Hospital	4	
Strategic report	4	
Structure, governance and management	13	
Process for awarding grants	15	
Fundraising approach and our supporter promise	15	
Fundraising regulation and complaints	17	
Reserves	18	
Acknowledgements	18	
Statement of Trustees' responsibilities	21	
Independent Auditors' report	22 - 23	
Statement of financial activities	24	
Income and expenditure account	25	
Balance sheet	26	
Cashflow statement	27	
Notes to the financial statements	28 - 50	

# Annual report and financial statements Year ended 31 March 2019

Trustees Mervyn Walker (elected), Chairman

Andrew Ballheimer (elected)

Sir Thomas Boyd-Carpenter KBE (appointed) (retired 20 July 2018)

Tony Briam (elected)
Noland Carter (elected)

Dr Lee-Ann Coleman (elected)

Declan Flanagan (appointed ex officio) (retired 12 August 2018)

Professor Ian Grierson (elected)

Vicky Hastings (elected)
Michael Izza (elected)

Dr Robert Jones (appointed)

Professor Carrie MacEwen (elected 4 June 2019)

Colin Maclean OBE (elected)

Johanna Moss (appointed ex officio)

David Probert (appointed ex officio)

Dr Virginia Spence-Jones (appointed)

Nick Strouthidis (appointed ex-officio 13 August 2018)

Professor Sir Eric Thomas (elected)

Company registered number 7543237

Charity registered number 1140679

Registered office 162 City Road, London, EC1V 2PD

Principal office Kemp House, 152-160 City Road, London, EC1V 2PD

Management group Robert Dufton Chief executive and company secretary

Gordon Burns Director of finance and resources

Rachel Jones Director of development

Dr Ailish Murray Director of research and grants management

Auditors Haysmacintyre LLP, 10 Queen Street Place, London, EC4R 1AG

Bankers The Co-operative Bank, 2nd Floor, St Paul's House, 10 Warwick

Lane, London, EC4M 7BP

Barclays Bank, 1 Churchill Place, Canary Wharf, London, E14 5HP

**Solicitors** Stone King LLP, Boundary House, 91 Charterhouse Street, London,

EC1M 6HR

Lead investment managers J P Morgan International Bank Ltd, 1 Knightsbridge, London, SW1X

7LX

## Trustee's report Year ended 31 March 2019

The Trustees (who are also Directors for the purposes of Company law) present their annual report together with the audited financial statements of Moorfields Eye Charity (the Charity) for the year ended 31 March 2019. This report incorporates the requirements of the Strategic Report as required by Company Law.

The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements; the requirements of the charitable company's governing document; and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective January 2015).

#### Constitution

The Charity is a company limited by guarantee (No. 7543237) and a charity registered with the Charity Commission (No. 1140679) and was formed on 3 March 2011.

Under a Charity Commission Scheme dated 31 December 2015, the assets of Special Trustees of Moorfields Eye Hospital (Regd. Charity No. 228064) ('Special Trustees') and its linked charities were transferred to the Charity. As at 31 December 2015 the Special Trustees ceased to exist and the newly merged charity also became independent of the Department of Health, it no longer being an NHS-linked charity.

Until 1 January 2016 the Charity had no staff of its own, and the Charity's work was carried out by staff provided by Moorfields Eye Hospital NHS Foundation Trust, under a service level agreement or by other suppliers under contracts for services with the Charity. From 1 January 2016 the Charity started a process of transition to having its work carried out by staff employed directly by the Charity. As the final step in that process, by mutual agreement, the fundraising Service Level Agreement with Moorfields was terminated on 31 March 2017 and the employment of the Moorfields fundraising staff was transferred to the Charity under the TUPE regulations (with effect from 1 April 2017).

## **Objectives and activities**

The Objects of the Charity as stated in its Articles of Association are as follows:

The relief of sickness or suffering, the advancement of health and the advancement of education and research in relation to health and health-related sciences by any charitable means for the public benefit in particular but without limitation by the support of charitable purposes relating to Moorfields Eye Hospital NHS Foundation Trust.

Our mission is to enable Moorfields Eye Hospital NHS Foundation Trust ('Moorfields') to continue to provide the best care for patients and their families and to help ensure it, in partnership with its research and education partner, University College of London's Institute of Ophthalmology ('the UCL Institute of Ophthalmology'), remains a world-class centre of excellence for ophthalmic research and education for the benefit of its current and future patients and people with eye-health conditions around the world. Charitable funds are typically used to support leading-edge research and education; purchase specialist equipment; develop better facilities for patients and the research infrastructure; fund specialist staff to care for patients, undertake research or carry out pioneering new roles; and fund the development and welfare of Moorfields staff

#### **Public benefit statement**

The Trustees confirm they have paid due regard to the Charity Commission's general guidance on public benefit and have complied with their duty under section 17 of the Charities Act 2011.

Charitable activities undertaken by the Charity are the award of Grants, details of which are set out in this report on pages 8 and 15 below. The Trustees are satisfied that all such activities provide a public benefit, given the relationship the charitable expenditure has to the enhancement of current and future healthcare for patients with eye problems.

Moorfields is the leading NHS eye hospital in the UK, seeing several hundred thousand patients a year and the contributions made by the Charity go to help these patients receive better treatment. The contributions made by the Charity to the research and education carried out by Moorfields and the UCL Institute of Ophthalmology also benefit these patients and the eye-health of people around the world.

### Trustee's report (continued) Year ended 31 March 2019

#### **About Moorfields Eye Hospital**

Moorfields is the leading provider of eye health services in the UK and a world class centre of excellence for ophthalmic research and education. The trust's reputation for providing the highest quality of ophthalmic care has developed over 200 years.

Moorfields plays a leading role in the training and education of eye care professionals, integrating with strategic partners across its network to teach the eye specialists of the future. With their partners at the UCL Institute of Ophthalmology, they are a national and international centre for research into eye conditions and treatments, leading one of the strongest and most extensive ophthalmic research programmes in the world. Moorfields and the UCL Institute of Ophthalmology have one of the highest measures of scientific productivity and impact in the world for eye research activity. Moorfields launched their five-year strategy in July 2017 with a new purpose, 'working together to discover, develop and deliver the best eye care'. This document became the base for the Charity's own strategy described below.

In 2018/19, over 780,000 patients visited 31 Moorfields NHS sites. The outpatients departments were the busiest, receiving nearly 600,000 attendances. In the A&E department, over 97,000 patients were seen for treatment. The 2018/19 the Friends and Family survey found that Moorfields provided positive care in all areas with: Inpatients (99.4%); A&E (93.3%); Outpatients (96.9%); and Paediatrics (97.9%).

#### **Care Quality Commission (CQC)**

Moorfields Eye Hospital has been rated outstanding for being effective by the CQC following their most recent inspection. Overall the trust received a rating of good, and the CQC highlighted that all of the trust's inspected services were rated as either good or outstanding.

Moorfields at City Road was also recognised as being outstanding in the domain of being effective overall. Moorfields at Bedford and St George's improved from 'Requires improvement' to 'Good' overall and surgical services at Moorfields at Bedford were rated outstanding for being effective.

#### Strategic report

#### Strategy and objectives

Our sight is a critically important sense. Sadly sight loss is an increasing reality for many people. In the UK an ageing population is adding to the challenge, resulting in greater and more complicated demand for eye services. This is why we are motivated by the core belief that people's sight matters.

In November 2017, the Trustees set out our plans for the years 2018 to 2024 in our first published **Moorfields Eye Charity Strategy: People's Sight Matters**, inspired by Moorfields' strategy, **Our Vision of Excellence**, which we used as our starting point. The strategy for 2018-2024 sets out our core belief which is "people's sight matters" and our organisational purpose to support Moorfields to discover, develop and deliver the best eye care.

Our strategy presupposed the continued importance of philanthropic support to enable us to realise our ambitious plans for 2018-2024. Our vision is to provide a new world class facility in London's medical and scientific quarter by 2024, working in partnership with Moorfields and its academic partner, University College London's Institute of Ophthalmology. The facility will provide integrated clinical care, teaching and research in eye health to benefit millions of current and future patients in London, the UK and across the world.

We have set ourselves five main objectives, listed in order of priority:

- 1. Work in partnership with Moorfields and UCL to create a new world class integrated clinical care, teaching and research facility;
- 2. Be the leading charity for research into eye health, supporting the pioneering work of Moorfields and UCL to make new discoveries and turn new knowledge into treatments to improve eye health and wellbeing outcomes for patients of Moorfields and around the world;
- 3. Support Moorfields staff in the delivery of outstanding and safe patient care and patient experience;
- 4. Support Moorfields to share its knowledge and to inspire and develop tomorrow's experts;
- 5. Work with Moorfields to shape national policy to increase resources allocated to eye health.

## Trustee's report (continued) Year ended 31 March 2019

We have two further supporting objectives:

- 6. Maximise sustainable and flexible support for Moorfields and UCL;
- 7. Attract, retain and develop talented and innovative people.

Moorfields has occupied its City Road building since its construction in 1899, and a combination of steadily increasing demand for its services and changes to the nature of ophthalmic treatments mean that the ageing building is no longer fit for purpose in terms of size, layout, supporting infrastructure or the quality of its fabric. The UCL Institute of Ophthalmology moved to an adjacent building in the 1980s.

If Moorfields is to continue to treat conditions that no other hospital in the country can tackle; if it is to continue to conduct outstanding and ground-breaking research into eye disease and therapeutic interventions with the UCL Institute of Ophthalmology; if it is to develop its education and training; and if it is to meet the needs of a growing patient population while enhancing the efficiency and effectiveness of the care it provides, then Moorfields and UCL need to develop a new state-of-the-art hospital, education and research facility in London at the earliest possible opportunity.

Philanthropy will play a key role in the delivery of this new integrated research, education and clinical care centre in London that will be home to both Moorfields and the UCL Institute of Ophthalmology; the expansion and development of research activities across the site; and the support of training and education as Moorfields is a major force in teaching the eye specialists of the future.

Recognising the once in a lifetime opportunity a new facility offers Moorfields and UCL, the Charity is playing a lead role in supporting the delivery of this new centre, including through a £100m fundraising campaign in partnership with UCL. The new facility has a working title of Oriel and is referred to as such throughout this report.

#### **Business model**

The Charity supports research work at Moorfields and the UCL Institute of Ophthalmology which will lead to improved understanding of eye conditions and development of treatments. This work is funded through a grant application process.

The Charity continues to be an active fundraising charity, seeking funds from donors with an interest and engagement in the work of Moorfields. The Charity is also enabled under the Charity Commission Scheme to receive donations and legacies in the name of Moorfields.

To support these activities and to provide strong governance the Charity employs staff to carry out financial, information management and governance functions. These people support the wider staff groups, the Management Group and the Trustees in their roles.

#### Risks and uncertainties

The Trustees consider the major strategic, business and operational risks that the Charity faces. During the year the Trustees have continued to review the Risk Policy and the methodology for recording and assessing risks faced by the Charity. Regular reports are produced so that all necessary steps can be taken promptly to manage any risks.

The most significant uncertainty for the Charity at the start of the year was around progress in securing the new site for Moorfields. This was having a significant impact on the Charity's ability to make progress on the joint fundraising campaign to be launched with UCL. During the year, agreement was reached over the preferred site at the St Pancras hospital, placing Moorfields and the Institute in proximity to other research organisations, colleges and the main UCL campus.

Our income is subject to volatility as we rely on the generosity and philanthropy of individuals and organisations for our fundraising; and our legacy income can never be predictable by its very nature. We work hard to engage with our supporters and explain our work to show how their generosity has a positive impact for people's eye health. In this way we aim to maintain and grow our levels of support. We are always grateful where people have told us they wish to remember us in their will and when the time comes we are careful to recognise as income only those amounts that we can be sure will be received.

## Trustee's report (continued) Year ended 31 March 2019

Other than grant awards, the most significant expenditure incurred each year is in relation to staff costs. The Charity faces the risk of increasing costs through salary pressure and rises in the purchase price of other supplies. Salaries are set at the start of each year and where practical the price of other supplies is agreed in advance through the use of supplier quotations and tendering.

The major assets of the Charity are the fixed asset investments. Market conditions for our investment portfolio remain volatile and uncertain but the Investment Committee works with our Investment Advisors to ensure that we are able to react to significant unforeseen events.

The Charity monitors the fundraising and data protection regulatory environment and during the year new and revised policies and procedures have been adopted to ensure we meet the new requirements and to minimise the impact of changes on our operating activities.

#### Environment, employees and social, community and human rights issues.

The Charity follows the Moorfields policies on the environment, employees and social, community and human rights issues. With the help of all our staff we have developed and produced a full range of Human Resources policies and, for the first time, our own Staff Handbook.

We undertook a second staff survey in March 2019, to build on our learning from the initial survey in 2018. We had shared the results with our staff to develop our plans to meet any areas of concern that had been raised. For the 2019 survey we used the same framework and questions to gauge the impact of our joint actions. In a small team we believe it is important for our staff to be able to work together, ensuring we all learn from the outcomes and establish continuously improving staff relations. The results of the 2019 survey showed improvements in many areas and there were no areas where staff satisfaction had reduced. The full results of the 2019 survey will be considered at our meeting in July.

The Investment Portfolio parameters forbid direct investment in tobacco-related companies, but there may be tobacco-related investments within the discretionary portfolios managed by our investment managers. This is monitored by the Investment Committee.

#### **Diversity**

The Board and Management Group are made up as follows:

As at the date of this report	Total	Male	Female
Trustees (Directors)	16	11	5
Senior Managers	4	2	2

#### **Remuneration of Staff**

A Remuneration and People Committee was established in 2018 and has taken responsibility for considering all aspects of remuneration for the Charity, providing recommendations to the Board where necessary. Remuneration for all our staff is set using guidance from Moorfields Human Resources department and with information available for similar roles across the charity sector. We set out to pay our staff fairly for the work they carry out and with reference to their qualifications and experience.

The salary of the Chief Executive, who is the highest paid member of staff, is set by the Trustees having taken into account his role and responsibilities, the size and nature of the Charity, and comparisons with others in the same sector. The salaries of other members of the Management Group are similarly set by the Remuneration and People committee in consultation with and on recommendations provided by the Chief Executive.

We believe it is appropriate to show ratios relating to salary fairness each year, both remuneration levels and gender pay, despite not being required to do so because of the size of our workforce. Having only 23 employees though means small changes each year can create wide variations in the results.

## Trustee's report (continued) Year ended 31 March 2019

The remuneration ratio (defined as the multiple between the highest pay to median pay), is widely considered to be a good indicator of pay fairness. The median salary for our staff is calculated as £38,750 (2018: £42,420). We employ a relatively higher number of medium/higher paid staff and we do not employ service delivery staff, and both of these factors give us a relatively high median. The highest salary is £105,080 (2018: £103,200), which gives the Charity's remuneration ratio as 2.7:1 (2018; 2.4:1).

Another measure of pay fairness is Low Pay/High Pay Remuneration ratio. The most common calculations are:

- Compare the mean average of the lowest paid 10% of staff with the mean average of the highest paid 10%. We have used the three highest and three lowest for our calculations giving a ratio of 4.14:1 (2018: 5.27:1);
- Compare the lowest with the highest paid member of staff, giving a ratio of 5.5:1 (2018: 5.1:1).

The proportion of women employed in each pay quartile is as follows:

	Percentage who are women			
Quartile	2019	2018		
Top quartile (highest paid)	67%	50%		
Upper middle	83%	100%		
Lower middle	83%	20%		
Lower quartile (lowest paid)	100%	100%		

## **Going Concern**

After making appropriate enquiries, the trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies note.

#### Performance in the year

A summary of our financial performance, before movements in the value of our investments, over the last five years is set out overleaf.

During the year, the Trustees approved grants totalling £2.7m (2018: £2.4m). This figure, and the comparative figure, are stated before commitments released in each year and before adjustments for net present values in the current and prior years. The section of this report on grant activities in the year, and notes 4 and 14 of the financial statements, give details of the range of activities funded by the Charity during the year. The level of grant awards in each year is dependent on the type and size of research projects being brought forward. 2017 had included our commitment to support the London Project, which was a significant award and distorts the comparison with other years both before and after.

The principal funding sources in 2019 were receipts from donations £3.44m (2018: £2.45m) and legacies of £3.04m (2018: £1.78m). Our total income in each year is highly dependent on the level of major donations and legacies.

Our fundraising costs are relatively consistent and form our largest operational cost. Support and costs of governance have fallen from 2018, which had included costs associated with the CRM procurement, legal advice regarding fundraising, GDPR and Oriel, and the recruitment of staff and Trustees.

## Trustee's report (continued) Year ended 31 March 2019

Five year financial summary	2019 £'000	2018 £'000	2017 £'000	2016 £'000	2015 £'000
Income and endowments from					
Donations	3,440	2,452	2,992	3,146	2,817
Legacies	3,044	1,776	3,257	2,072	3,336
Events	255	303	318	315	221
Raffles and Lotteries	57	63	76	74	0
Investments	288	277	276	230	234
Total Income	7,084	4,871	6,919	5,837	6,608
Expenditure					
Fundraising	1,250	1,113	1,216	1,159	944
Grants	2,253	1,850	7,635	2,911	3,919
Support and other	596	738	393	336	298
Total expenditure	4,099	3,701	9,244	4,406	5,161
Net surplus/(deficit) before investment gains/(losses)	2,985	1,170	(2,325)	1,431	1,447

#### Criteria used to assess Success in the Year

#### During the year

- Grants awarded in competition were assessed by the Scientific Advisory Panel against criteria set by the Trustees.
- Fundraising income was assessed against a budget agreed by the Trustees.
- Expenditure on fundraising and charitable activity support costs was measured against a formally agreed budget.
- Investment returns, total returns, were measured against a 3-year rolling target of RPI + 3.5% and compared against benchmark indices for context.

#### Grant activities in the year

In 2018, working with Moorfields and UCL Institute of Ophthalmology, we introduced our new research funding programmes refocussing our support to underpin and enhance new and evolving research, and support those who undertake it.

As part of this, we introduced a new scheme, Springboard Awards to provide funding for researchers to develop novel ideas and generate preliminary data which will underpin and form part of larger, competitive, project grant applications to other external funding bodies. We will also continue to provide funding for equipment grants with a renewed focus on multi-user equipment. These grants will ensure that the most up to date equipment is available to all researchers, foster collaborations and help support core equipment facilities which will become self-sustaining.

To encourage and support the outputs and outcomes of current research, Moorfields Eye Charity's Research Enhancement Awards will provide funding towards the publication of research findings to maximise impact and availability of these results. Support for small pieces of equipment will also be available where the potential to greatly enhance research and likelihood of securing future external funding is demonstrated.

Alongside our PhD Studentships we are expanding our support of early career researchers with new Research Training Fellowships for clinical and allied health professions who have demonstrated the potential to pursue a career as an academic clinical or allied health professional.

## Trustee's report (continued) Year ended 31 March 2019

In supporting the next generation of research leaders, the Moorfields Eye Charity Career Development Awards offer an exciting opportunity. These awards will provide short term support for science researchers, clinical and allied health professionals who are already on a career track to be future leaders in ophthalmic research and clinical practice. The funding is intended to enable these individuals to focus on their research and to capitalise on other external funding opportunities to develop their research programmes.

After accounting for grant commitments released in the year and the opening and closing adjustments for net present value, adjustments to reflect the current cost of grants payable in future years, grants of £2.25 million were made during the year (2018: £1.85 million) as set out below:

	2019	2018
Research	£1.66m	£0.82m
Equipment	£0.21m	£0.87m
Patient and Staff Welfare	£0.19m	£0.09m
Education	£0.19m	£0.07m
Capital Grants	£Nil	£Nil

Following guidance in SORP 2015, grant liabilities accounted for as creditors falling due after more than one year have been discounted to their net present value. The discount rate used was 3.8% (2018: 4.3%) being the average rate of total return expected on the Charity's total investments and included in the budget for the coming year.

#### Allocation of grants against funds

We endeavour to utilise the most restricted income before those funds with less restrictions. With the implementation of greater monitoring and reporting capabilities from our new database, the intention is to ensure even greater use of restricted donations before unrestricted income where ever possible.

#### Overview of grants made

Over the year we have issued one hundred and one grants across twenty broad funding programmes. The total level of commitments made was £2.78m or just under 50% of the £5.68m budget. The overall commitment to budget spend percentage was 46% for planned grant making activity; while it was 52% for philanthropy supported activity.

Grants awarded in 2019 were either to Moorfields or to UCL. Grants to UCL are mainly made to the UCL Institute of Ophthalmology. The table below provides an overview of grant queries and applications processed by the grants and research team over the last year.


	Awarded	Not awarded	Queries (open/closed)	Not progressed	Total
Moorfields	79	14	7	3	103
UCL IoO	22	5	5	3	35
Total	101	19	12	6	138

Following last year's reduction in the level of research grants awarded, from £4.6m in 2017, we are pleased to have awarded £1.66m in 2019, (net of grants released and the present value adjustments) closer to our expected £2.0m level of research grants each year. We are always dependent on projects being brought forward for consideration.

The support MEC provides in terms of grant making activities covers a number of the objectives outlined in our strategy. The table below provides details on the split of awarded grants according to the objective the work primarily supports and the chart presents the percentage of total awarded across all schemes. This data shows that at 83% of our grant making funds supports objective 2 - to be the leading charity for research into eye health.

## Trustee's report (continued) Year ended 31 March 2019

#### Percentage spend by objective



#### Awarded grants by objective

	No.	Total awarded
Objective 2 - Be the leading charity for research into eye health	38	£2,291,610
Objective 3 - Support Moorfields staff in the delivery of outstanding and safe patient care and patient experience	13	£298,812
Objective 4 - Support sharing knowledge to inspire tomorrow's experts	50	£185,229

Throughout the year the scientific advisory panel considered applications from the following grant making schemes:

Considered at a panel meeting	Considered on rolling basis
<ul> <li>Springboard award</li> <li>Equipment grant</li> <li>PhD studentship</li> <li>Career development award</li> <li>Research training fellowship</li> </ul>	<ul> <li>Research enhancement award – publications</li> <li>Research enhancement award - equipment</li> </ul>

The funding rates for these competitive and rolling grant making programmes are outlined in the table below, showing an overall success rate of 73% for these programmes.

Host institution	Awarded	Not awarded	Total	Success rate
Moorfields	6	2	8	
UCL IoO	13	5	18	
Total	19	7	26	73%

As part of our ongoing work to promote our funding schemes and attract new applicants, we have made increased efforts to advertise and engage with potential applicants. Over the last year, of the 19 grant recipients from our competitive and rolling grant making programmes (excluding travel grants) seven were first time grant applicants to the charity. Of the seven grants which were not awarded, three applicants were new to the charity.

The table below shows awarded grants from all funding programmes by host institution:

Host institution	No.	Total awarded	Average Award	Min. Award	Max. Award
Moorfields	70	£1,160,101	£16,573	£22	£405,900
UCL IoO	22	£1,615,550	£73,434	£3,360	£188,795
Total	101	£2,775,651			

The general trend is for more applications from and awards of higher level to be issued to the UCL Institute of Ophthalmology. When awarded grants from across all funding programmes are collated, the figure for Moorfields is much higher in terms of number of individual awards. However, this figure is skewed by the research travel grants which alone constitute the largest number of grants we issue through a single programme and these are only available to staff of Moorfields.

## Trustee's report (continued) Year ended 31 March 2019

#### Categories of work

All grant applications are classified according to their category of work. During the year we have focused primarily on research grants but we are currently reviewing the adoption of suitable defined classifications for non-research grants to ensure consistent year-on-year comparisons can be made across the full portfolio of funded grants.

The table below sets out how our grants for 2018-19 were awarded by category of work:

Category of work	No.	Total awarded
Pre-clinical / basic research	26	£1,711,267
Translational research / proof of concept to phase IIa trials	6	£314,630
Multi-user equipment	3	£209,415
Technology and innovation	4	£178,892
Education	1	£120,000
Patients/Public	8	£130,321
Staff	7	£71,474
Research travel grant	46	£39,652

It is clear that pre-clinical/basic research is a primary category supported by the charity both in terms of number of grants but also overall value. Research travel grants have been included here for information only as data is not collected for these grants using the defined categories here.

#### Areas of research

All research grant applications are also classified according to the disease or research areas of focus. The data analysis below is based only on what is considered the single majority/principle area. The average award per area of research column shows that, by and large, the average award is higher in the areas which receive more grants. Exceptions include ocular motility / visual processing which indicates that while there were six awards, the level of funding per award was low. The following table shows, in ascending order of number of grants, the primary research areas supported by number of grants awarded.

Area of research	N	Total Awarded	Average award
Ocular cancer	1	£275	£275
Adnexal/extra-ocular	2	£644	£322
Neuro-ophthalmology / optic neuropathies	3	£2,558	£853
Diabetic retinopathy	4	£102,287	£25,572
Ocular inflammatory disease	4	£114,726	£28,682
Glaucoma	5	£14,040	£2,808
Corneal / ocular surface disease	6	£98,714	£16,452
Ocular motility / visual processing	6	£3,932	£655
Paediatrics	7	£144,578	£20,654
Genetics / inherited eye diseases	12	£385,223	£32,102
Retinal / vitreo-retinal	14	£386,615	£27,615
Age related macular degeneration	19	£1,174,322	£61,806
Total	83	£2,427,914	£2,427,914

## Trustee's report (continued) Year ended 31 March 2019

#### **Fundraising activities**

The Charity is extremely grateful for the generous support we receive from our patients, staff, friends, charitable trusts and foundations, and corporate partners. During the year we have received support through:

- Major gifts from individuals, trusts and foundations, and companies.
- · Legacies, where individuals have made provision to remember Moorfields in their wills.
- Individual donations, often received in response to a specific appeal.
- Regular donations, usually received on a monthly basis.
- Our winter raffle and weekly lottery.
- Our bespoke events including our sponsored walk, Eye to Eye and Moorfields Tea.
- Community fundraising such as cake sales, music concerts and skydives.
- Challenge events including abseils, runs and bike rides.
- · Organisational partnerships.

#### Review of fundraising performance against objectives

Income raised by the Fundraising team was £6.79m (2018: £4.59m). The table below compares performance against the budget for the year (target) and the performance for the prior year.

	2019	Target	% Target	2018	% Change
Donations	£3.44m	£3.03m	113.5%	£2.45m	40.4%
Events	£0.25m	£0.35m	71.4%	£0.30m	(16.7%)
Legacies	£3.04m	£2.00m	152.0%	£1.78m	70.8%
Raffle and Lottery	£0.06m	£0.13m	46.2%	£0.06m	-
Total	£6.79m	£5.51m	123.2%	£4.59m	47.9%

We have continued to amend our fundraising practices and activities, responding to the changing regulations introduced under the new General Data Protection Regulations, and adapting to the introduction of our more structured database. Towards the end of the year we also began to operate with a full staffing establishment in the fundraising teams. Our budget for the year had again assumed that the purchase of the new site for Moorfields would have progressed to a point which would have allowed the Charity and UCL to launch their joint fundraising programme for the relocation. The progress made in the year, identifying and agreeing the site, design team and availability of funding from the Department of Health and Social Care has begun to raise the profile of Oriel for the new financial year.

Legacy income included an accrual of £2.13m (2018: £2.02m.). Legacy income is unpredictable and the Charity is unable to control the amounts notified or receivable in any one year.

#### Investments

The Charity's investment strategy is to seek a total return while accepting a moderate level of risk.

The Investment Committee provides detailed oversight of the performance of the Charity's investment portfolio and its performance against the Charity's strategy. As part of that process the Committee conducts a rolling programme of meetings with the Charity's fund managers.

## Trustee's report (continued) Year ended 31 March 2019

During the year ended 31 March 2017 the Investment Committee engaged Stanhope Capital LLP, an independent consultant who specialises in Charity investments, to aid them in a review of the investment strategy. The results of that review were presented to the Trustees in September 2016 and it was agreed that the target of RPI +3.5% remained appropriate for the long term portfolio but that changes in the appointed managers and their underlying investment objectives would be required to achieve that return. Recognising the decision to provide support to Moorfields for the acquisition of the Oriel site, the Trustees decided to retain £12 million as a cash deposit to remove the risk of market volatility on these funds.

The changes were actioned during the year ended 31 March 2018 and the Charity's investments are now divided into funds for long term and for short term investment. This approach continued during the year ended 31 March 2019.

For the long term a portfolio of investments has been established, with JP Morgan as the custodian of the entire portfolio, and with a target equity weighting of 60-70%. The long term investment portfolio is structured as follows:

Investment Manager		Weighting	Value at 31 March 2019 £'000	Value at 31 March 2018 £'000
JP Morgan	Discretionary portfolio	50%	£18,994	£17,941
Troy Asset Management	Absolute fund (with objective to achieve growth in real terms)	30%	11,231	£10,754
Artisan Partners Global Funds	Equity investments for a real return	20%	£7,750	£7,193

The average three year rolling target of RPI+3.5% for the long term portfolio was first set in 2012 and continues to be reviewed by the Investment Committee.

In 2019 the JP Morgan discretionary portfolio achieved a return of 1.07% (2018: 4.23%). Troy Asset Management funds have increased by 4.43% (2018 (part year): fell by 4.87%). Artisan Global Value funds have increased by 6.68% (2018 (part year): fell by 3.23%). All three funds faced volatile results throughout the year, with December 2018 being particularly difficult, but all three had acted defensively in the year by reducing our overall exposure to equities to 54.6%. In the final quarter, all of the funds have shown growth, recovering the falls incurred in December.

The overall return of the portfolio for the year, net of fees, was 3.3% (2018: 1.04%) whereas the 3 year rolling RPI+3.5% was 6.44%. Performance of the ARC Charity Sterling Balanced Index (for charity investments with equity weightings of 40% to 60%) for the year was 3.94% (2018:1.31%) which compares with the performance of our long term investments and reflects the second year of difficult trading conditions described above.

The short term investments are made up of term deposit accounts with JP Morgan. As noted above, the Trustees supported the proposal to hold £12m as a cash deposit for use in the Oriel site purchase. This money is held in a 95-day notice account earning interest at a rate (0.75%) linked to the Bank of England base rate. Operating cash held on deposit with JP Morgan is held in a 35-day notice account earning interest at a rate (0.65%) linked to the Bank of England base rate.

#### Structure, governance and management

#### Structure

The Trustees who have served the Charity during the year and since the year-end are set out on page 2. Moorfields Eye Hospital has the right to appoint up to seven Trustees and there can be up to eleven further elected Trustees, provided always that the elected Trustees are in the majority. The Trustees appoint the Chairman (who must be an elected Trustee). Decisions are taken by a majority of Trustees present at regular meetings and procedures are in place to ensure that such decisions do not enable the appointed Trustees to exercise effective control.

## Trustee's report (continued) Year ended 31 March 2019

Elected Trustees are recruited through open recruitment when vacancies arise and nominations are agreed by all Trustees. On appointment new Trustees undertake an induction process which includes the provision of necessary documentation, meetings with the Chief Executive, other senior charity staff and with senior members of Moorfields staff. The induction is designed to ensure that new Trustees understand the role of the Charity and how it works to support Moorfields.

Declan Flanagan, retired from his role as Moorfields Eye Hospital's Medical Director in August 2018 and so ceased to be an appointed trustee of the Charity. His successor as Medical Director, Nick Strouthidis, was appointed by Moorfields Eye Hospital as a trustee ex-officio. Nick is a consultant ophthalmologist and a former director of the glaucoma service at Moorfields Eye Hospital, and a clinician scientist at the NIHR Biomedical Research Centre at Moorfields and the UCL Institute of Ophthalmology. His research interests are in glaucoma.

Professor Caroline (Carrie) MacEwen was appointed as a trustee of the charity in June 2019, and will now step down from her current role on the scientific advisory panel. She is a consultant ophthalmologist at Ninewells Hospital, Dundee and holds an honorary chair as head of the department of ophthalmology at the University of Dundee. Professor MacEwen serves on a number of national bodies in ophthalmology, health and medical education. She is currently chair of the council of the Academy of Medical Royal Colleges and is the immediate past President of the Royal College of Ophthalmologists.

#### **Committees**

The Trustees have established a committee structure to support the Trustees in the governance of the Charity. The committees, and members who served during the year, are set out below:

Audit and Risk	Fundraising and Communications	Grants	Investment	Remuneration and People	Oriel
Tony Briam (Chair)	Professor Sir Eric Thomas (Chair)	Dr Lee-Ann Coleman (Chair)	Noland Carter (Chair)	Mervyn Walker (Chair)	Tony Briam (Chair)
Michael Izza	Andrew Nebel	Declan Flanagan (retired August 2018)	Vicky Hastings	Vicky Hastings	Sarah Barzycki (until April 2019)
Mark Johnstone	David Probert	Professor Ian Grierson	Mervyn Walker	Colin Maclean	Eric Thomas (from Sept 2018)
Colin Maclean	Dr Virginia Spence-Jones	Dr Robert Jones		David Probert	Mervyn Walker
Mervyn Walker		Dr Nick Strouthidis (from August 2018)			
		Professor Carrie MacEwen (from June 2019)			

Each Committee has agreed Terms of Reference setting out their areas of responsibility and the limits of their delegated powers. Any Trustee may attend any Committee meeting as an observer.

Each Committee is enabled to appoint volunteer advisers as members to support our decision making and enhance the level of experience and knowledge within the membership.

The Grants Committee is supported by a Scientific Advisory Panel, who meet to consider applications for research funding. This is explained further below.

## Trustee's report (continued) Year ended 31 March 2019

At each Investment Committee meeting there is a presentation on investment performance by one of the three investment managers. Where it is considered necessary to consider the risks in the investment portfolios, or where investment proposals are being considered, joint meetings with the Audit and Risk Committee can be held.

The Remuneration and People Committee was established in 2018 to consider pay awards for all staff employed by the Charity, to consider other benefits offered, such as membership of pension schemes, and to consider policies and procedures relating to human resources.

The Oriel Committee meets to consider progress on the development of the new Moorfields facility and to review any implications for the Charity.

#### Governance and management

Our charity has seen a high level of change from the merger in 2016 through to 2018. This year we have been able to consider how we work together and with the people who work for the charity. We have seen policies:

- reviewed and updated in relation to data management, in response to the changes from the General Data Protection Regulations;
- created for human resources to ensure they are relevant for our people;
- and evolved in relation to fundraising, grants management and risk management.

We have again seen changes in our group of Trustees, welcoming new people as others have moved on or retired. Our Management Group has benefitted from a first full year in post and we are seeing the results of this in the quality of reports being presented to us at committee and Board meetings.

As referenced last year, we have invested in the development of a new customer relationship management system for use by the fundraising team and for future use by the grants management team. We were delighted to see this project was successfully completed to budget and feedback from users has been positive. This was a significant investment of both time and funds by the charity and the Trustees recognise the effort of all the staff and the impact this change has had on them during the year.

As we look towards the development of Oriel, and our own commitment towards raising funds for the development, we agreed it would be appropriate to support the refreshing of the profiles and branding for all organisations associated with Moorfields. This report has been refreshed to reflect our new style and we plan to refresh all of our branding, including our web-site and digital presence, in the coming months.

The Trustees have delegated day to day management of the Charity to the Management Group comprised of the Chief Executive, supported by three senior staff. The management group all attend meetings of the Board, presenting papers and participating in our discussions.

The Chief Executive, who is also the Company Secretary, reports to the Trustees on all administrative aspects of the Charity's operations, and is also responsible for keeping the Trustees informed about charity and other relevant law and procedures. The Trustees, Chief Executive and other members of the Management Group attend relevant courses and seminars, to maintain the required skills for the proper governance and financial control of the Charity.

## **Process for awarding grants**

Research and equipment grants are awarded by the Grants Committee using its delegated powers from the Trustees. Awards are made, in competition, after applications have been: assessed by the Charity's research and grants team; then reviewed by the Charity's Scientific Advisory Panel ('the Panel') or by agreed scientific advisers.

Other grant making activities include patient welfare and staff support grants which are considered and approved for funding by the Grants Committee or, under delegated authority, by the Charity's CEO or Chairman of Trustees.

Where grant applications are funded from donations that are restricted to the purpose(s) outlined in an agreement with a donor, the applications are not normally reviewed by the Panel. Instead the Trustees delegate the scientific review of such applications to a team consisting of the Director of Research and Development at Moorfields Eye Hospital, the Director of the UCL Institute of Ophthalmology and the Chair of the Panel (currently Professor Ian Grierson – who is a Trustee of the Charity).

### Trustee's report (continued) Year ended 31 March 2019

All funding decisions are formally minuted at a Grants Committee meeting.

The Panel meets three times a year and considers research and equipment applications in order to provide funding recommendations to the Grants Committee. The Panel also reviews interim and final grant reports with increasing scrutiny being placed on the layperson's summary and outcomes.

The Panel is chaired by Professor Ian Grierson and the independent Panel members serving during the year were:

- Professor Caroline (Carrie) MacEwen, University of Dundee
- Professor Philip Murray, University of Birmingham
- Professor Colm O'Brien, University College Dublin
- Professor Luminita Paraoan, University of Liverpool

## Fundraising approach and our supporter promise

We are extremely grateful for the generous support we receive from our supporters, patients, staff, friends, charitable trusts and foundations, and corporate partners. This support enables the funding of new equipment and pioneering research. It also supports the training of current and future researchers and healthcare professionals, development of Moorfields' staff to ensure the care they provide is outstanding, public education about eye health, and improving the experience for Moorfields' patients and their families. In addition it supports our key strategic priority to create a world class integrated care, teaching and research facility in central London, in partnership with Moorfields Eye Hospital NHS Foundation Trust and University College London. This is underpinned by the launch of the charity's first six year strategy 'people's sight matters' complementing Moorfields Eye Hospital's new strategy 'our vision of excellence'.

We are committed to providing our supporters with the very best donor care. We want our supporters to feel that their support is recognised and valued and that they are kept updated on how charitable support is helping to shape the future of eye care. Our supporters are critical to our success. We are fully committed to being transparent and accountable to them. We actively ask our supporters how they would like to hear from us and what they would like to hear about ensuring that our communications are targeted and of interest.

Our relationship with our supporters is of the utmost importance to us and is reflected in our supporter promise:

#### We value your donations and will keep you informed

- We value every gift we receive, large and small, and seek to acknowledge and send thanks for all donations in a timely manner.
- We will be transparent about how we use your donations and we will always put your gift to work as quickly as we can.
- We will share news about Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology, the hospital's academic partner. We will also keep you informed about how charitable donations are benefitting patients and people with sight problems further afield.

#### We respect your right to privacy

- We will rely on legitimate interest to send marketing materials by post. In addition, in line with your
  preferences, we may communicate with you by post, email, text or telephone. If we phone you, we will
  always check first that you are happy to speak to us and that it is a convenient time to call.
- We will respect your wishes, so if you ask us not to contact you for marketing purposes we won't, unless it's a legal requirement.
- We only allow authorised agents who work on our behalf to access your personal data and will never
  exchange your details with, or sell or rent your data to, any other commercial or charitable
  organisations. We have a Data Protection Policy (DPP) in place, detailing the ways in which the charity
  may process your data and how you can manage this. Our DPP can be viewed on our web-site and
  information on how we process data is available on request.

## Trustee's report (continued) Year ended 31 March 2019

#### We will take accountability for our actions

- We will always take action if any external supplier acting on behalf of Moorfields Eye Charity fails to meet our standards.
- When we get things wrong, we will be up front about our mistakes, apologise and act quickly to fix them.

Our fundraising activity is focused on the following key areas:

- Major gifts from individuals (both from existing and new supporters (both from within and outside our current supporter and peer networks), charitable trusts and foundations (through peer links, existing relationships, and through formal application procedures), and companies (through registered giving vehicles, via staff engagement, through formal application procedures and through peer links) with an interest in our work at a significant financial level.
- Legacies, through raising awareness around gifts in wills (both to existing supporters and visitors to the charity website), keeping in touch with known legacy pledgers (with events such as the legacy afternoon tea), and through the ongoing development of an engagement programme for those who have told us that they have, or intend to, remember Moorfields in their wills.
- Individual donations, often received in response to specific appeals (targeted at existing supporters) or through awareness raising of the charity undertaken by Moorfields Eye Hospital to its patients, visitors and trust membership.
- Regular donations, usually received on a monthly basis.
- Our winter raffle (promoted to our existing supporters, within the hospital and through the charity's website) and our weekly lottery programme (promoted in the same way we promote our raffle).
- Eye to Eye, our flagship bespoke sponsored walk (marketed to existing supporters, through the charity's website, to trust members, patients and staff, and promoted to local schools and businesses, and to the wider public through our social media channels).
- Community fundraising, providing support and information for people wishing to raise funds independently for the charity through events such as cake sales, music concerts and skydives.
- Challenge events including abseils, runs and bike rides (marketed to existing supporters, through the charity's website, and to Moorfields' patients and staff through publicity campaigns across Moorfields' sites, and to the wider public through our social media channels).
- Organisational partnerships including sponsorship and the donation of products for our fundraising events.

Our activities, and the processes which underpin them, are conducted under the legal basis of either consent or legitimate interest, as outlined in our data protection and fair processing policies.

We are committed to continually developing and enhancing our supporters' engagement and experience with the Charity and to exploring new and innovative ways of generating funds, so that together, we can continue to support Moorfields to discover, develop and deliver the best eye care.

#### **Fundraising regulation and complaints**

The charitable sector has been under particular scrutiny over its approach to raising funds and communicating with potential supporters. We are aware of the need to protect vulnerable persons in any fundraising we undertake and are continually taking steps to ensure our fundraising approach takes this into account. We continually review our methods of fundraising and communications to ensure that our approaches are appropriate, that we provide our supporters with the very best donor care and that we are compliant with both best practice and legislation.

We are a member of the Fundraising Regulator and fully comply with all relevant laws including the Data Protection Act 1998, the General Data Protection Regulation, and the Privacy and Communications Regulations 2003. We will also screen against the Fundraising Preference Service.

## Trustee's report (continued) Year ended 31 March 2019

We always strive for best practice in our fundraising and take complaints very seriously. Between 1 April 2018 and 31 March 2019, we received five complaints about the fundraising activity we undertook (2018: 11). Each complaint is investigated and answered in an appropriate and timely manner in line with the charity's Complaints Policy. All our complaints are reported to the Fundraising and Communications Committee of the Board of Trustees.

#### Reserves

The total funds of the Charity at the end of the year were £49.7 million (2018: £45.5 million). Of these funds £5.1 million (2018: £4.0 million) were Unrestricted Funds, including Designated Funds.

The Trustees' policy is to hold unrestricted reserves to cover planned operating expenses for two years. Much of the charity's unrestricted income is received through legacies and investment income which are both volatile sources of income. Two years of planned operating expenditure held as reserves enables the charity to be resilient in the event of a significant reduction in income which might otherwise result in the closure of the Charity and to continue to meet committed grant awards.

For 2019 the Trustees estimate the Reserves requirement to be £5.0 million (2018: £4.4 million), calculated for the year on two years of running costs included in the budget for 2019-20. Actual Reserves at the end of the year, being unrestricted funds less designated funds, were £4.6 million (2018: £3.5 million). The Trustees have agreed that appropriate costs be allocated to former Special Trustees Funds thus easing the burden of costs on Unrestricted Funds. In the coming year the Trustees will continue to keep the amount of Reserves under review.

#### **Funds transferred from the Special Trustees**

Following the Charity's merger with Special Trustees in December 2015, funds which were formerly considered as unrestricted in Special Trustees are now restricted, as their objects are narrower than those of the Charity. This restricted fund stands at £33.7 million at the end of the year (2018: £31.7 million).

#### **Designated Funds**

To support the future development of Moorfields the Trustees have previously designated £500k (2018: £500k) to enable the charity to contribute exceptionally to Moorfields' development.

#### **Acknowledgements**

The charity would like to thank the growing number of individuals and organisations who have generously supported our work over the last year. Your support has a significant impact on the work of Moorfields Eye Hospital and its research partner the UCL Institute of Ophthalmology.

Thanks to your help we are able to:

- fund new equipment and pioneering research;
- support the training of current and future researchers and healthcare professionals;
- support the development of Moorfields' staff to ensure the care they provide is outstanding;
- support public education about eye health;
- improve the experience for Moorfields' patients and their families; and
- support Moorfields' ambitious capital plans to create a world class integrated care, teaching and research facility in central London with its academic partner, UCL.

We are extremely grateful to those individuals who have generously supported Moorfields Eye Charity by remembering Moorfields in their will. Legacies form a significant source of income for the Charity and provide much of the funds we need to continue our work.

## Trustee's report (continued) Year ended 31 March 2019

We are particularly grateful to the individuals and organisations set out below, but also the many other supporters who would prefer to remain anonymous, who have supported us during the year.

Akari Therapeutics Mr & Mrs R J Ashton

Bill Brown 1989 Charitable Trust

Blue Water Energy Peter Butler

Simon and Jenna Butler

Sean Farrell and Marina Campbell

The Cadogan Charity

The Carmen Butler-Charteris Charitable Trust

Marti Clare

**Evans Management Ltd** 

Mr Gordon Gilby

Mr Albert Hausammann

The Helen Hamlyn Trust Mr & Mrs Stefanos Lekanidis

Marie-Louise von Motesiczky Charitable Trust

The Brian Mercer Charitable Trust
The Michael and Ilse Katz Foundation

The Michael Uren Foundation
In memory of Mrs Rubab Sultanali

Nurmohamed
Oak Foundation

Adam and Debbie Ripley

Eleanor Robbins

Shirley and John Sarks Fund

Miss Barbara Mary Wilmot Discretionary Trust Stephen and Elizabeth Archer in memory of

Marion Woods

We would like to thank all the staff, clinicians and academics at Moorfields and the Institute who have contributed to the charity's continuing success. With your support, we are able to ensure that Moorfields Eye Hospital remains at the forefront of eye care and research worldwide and has an impact on the global eye health agenda.

The Trustees would also like to thank:

- the volunteer advisers who are members of board sub-committees and the scientific advisory panel: Sarah Barzycki, Mark Johnstone, Professor Philip Murray, Andrew Nebel, Professor Colm O'Brien, Professor Luminita Paraoan and, until her appointment as Trustee, Professor Carrie MacEwen.
- the staff of the Charity, including those who left the Charity during the year; in particular Deborah Giles who had worked for Moorfields Eye Charity from the start and built our individual giving programme over eight years; Martin Mina, who developed our donor research and donor protection processes; Gaby Richardson, who has helped develop our fundraising events in the past two years; Catriona Parry who supported our fundraising teams and guided us through change arising from GDPR; Olivia Howarth who was our lead in the redesign of our branding with Moorfields; and Adrian Silk who helped us develop and introduce our new fundraising and grants database.

This year has seen the retirement of two of our long standing Trustees.

As noted last year, Sir Thomas Boyd-Carpenter retired on 20 July 2018. Sir Thomas was Chairman of Moorfields Eye Hospital NHS Foundation Trust from 2001 to 2008, a trustee of the Special Trustees from 2001 to 2013 and has been a Trustee and member of the Grants and Oriel Committees for the Charity.

Declan Flanagan stood down as a trustee in August 2018, following his retirement from the role of Medical Director at Moorfields. We are grateful for the huge contribution which Declan has made as a trustee, as a member of the grants committee and for his contribution to the success of Moorfields. We also congratulate him on his appointment as Vice President of the Royal College of Ophthalmologists.

## Trustee's report (continued) Year ended 31 March 2019

## **Appointment of auditors**

In accordance with the Companies Act 2006 a resolution proposing the reappointment of Haysmacintyre LLP as auditors for the year ended 31 March 2020 will be put to the members.

#### Disclosure of information to auditors

Each of the persons who are trustees at the time when this trustees' report is approved has confirmed that:

- so far as that trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- that trustee has taken all the steps that ought to have been taken as a trustee in order to be aware of
  any relevant audit information and to establish that the charitable company's auditors are aware of that
  information.

In signing this report Trustees are approving the strategic report in their capacity as company directors.

Approved by the Trustees and signed on their behalf by:

Mervyn Walker

My Val

Chairman

11 July 2019

## Statement of trustees' responsibilities Year ended 31 March 2019

The Trustees (who are also directors of Moorfields Eye Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company and the group's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

# Independent auditor's report to the members and trustees of Moorfields Eye Charity Year ended 31 March 2019

#### **Opinion**

We have audited the financial statements of Moorfields Eye Charity for the year ended 31 March 2019 which comprise the Statement of Financial Activities, the Income and Expenditure account, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2019 and of
  the charitable company's net movement in funds, including the income and expenditure, for the year
  then ended:
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Responsibilities of Trustees for the financial statements

As explained more fully in the Trustees' responsibilities statement set out on page 19 the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <a href="www.frc.org.uk/auditorsresponsibilities">www.frc.org.uk/auditorsresponsibilities</a>. This description forms part of our auditor's report.

#### Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

 the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or

# Independent Auditor's report to the members and trustees of Moorfields Eye Charity (continued)

Year ended 31 March 2019

the Trustees have not disclosed in the financial statements any identified material uncertainties that
may cast significant doubt about the charitable company's ability to continue to adopt the going
concern basis of accounting for a period of at least twelve months from the date when the financial
statements are authorised for issue.

#### Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees' Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (which incorporates the strategic report and the
  directors' report prepared for the purpose of company law) for the financial year for which the financial
  statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the Trustees' Report have been prepared in accordance with applicable legal requirements.

#### Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report (which incorporates the strategic report and the directors' report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the charitable company; or
- the charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

#### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Richard Weaver (Senior Statutory Auditor)
For and on behalf of Haysmacintyre LLP, Statutory Auditors

10 Queen Street Place London EC4R 1AG

## Statement of financial activities Year ended 31 March 2019

		Unrestricted	Restricted	Endowment	2019	2018
		funds	funds	funds	total	total
Income and and accomments from .	Note	£'000	£'000	£'000	£'000	£'000
Income and endowments from: Donations	2	652	2,788	_	3,440	2,452
Legacies	2	1,061	1,922	61	3,044	1,776
Events	2	127	128	-	255	303
Other trading activities:	2					
Raffles and lottery		57	-	-	57	63
Investment income	2	28	201	59	288	277
Total income	2	1,925	5,039	120	7,084	4,871
rotal income	2	1,925	5,039	120	7,004	4,071
Expenditure on:						
Raising funds:						
Fundraising	3	545	505	-	1,050	985
Investment management	3	25	119	56	200	128
	3	570	624	56	1,250	1,113
Charitable activities:	4					
Research		39	1,336	280	1,655	816
Equipment		100	113	-	213	874
Patient and staff welfare Education		46	148 191	-	194 191	90 70
Grants management		5	111	- -	116	96
Oriel		-	16	-	16	68
Governance and support costs	5	89	327	48	464	574
		279	2,242	328	2,849	2,588
Total expenditure		849	2,866	384	4,099	3,701
Net income/(expenditure)						
before investment gains and		1.076	0.470	(264)	2.005	1 170
losses		1,076	2,173	(264)	2,985	1,170
Net gains/(losses) on	0					
investments	9	27	1,137	62	1,226	434
Net income/(expenditure)		1,103	3,310	(202)	4,211	1,604
Transfers between funds		-	· -	-	-	-
Net movement in funds		1,103	3,310	(202)	4,211	1,604
Reconciliation of funds:		, -	, -	` '	,	,
Total funds brought forward		4,013	35,383	6,071	45,467	43,863
Total funds carried forward	16	5,116	38,693	5,869	49,678	45,467
Total fullus cameu forward	10	3,110	30,033	3,003	73,010	45,407

The accounting policies and notes on pages 28 to 50 form part of these financial statements.

Full comparatives for the year ended 31 March 2018 are included at Note 18.

## Income and expenditure account Year ended 31 March 2019

All Income Funds	Note	2019 Total	2018 Total
Income	Note	£'000	£'000
Donations		3,440	2,452
Legacies		2,983	1,474
Events		255	303
Other trading activities:	2		
Raffles and lottery		57	63
Interest and Investment income	2	229	211
Gains on investments	9	1,164	209
Gross income in the year	2	8,128	4,712
Expenditure on			
Raising funds	3	1,194	1,086
Charitable activities	4	2,521	2,580
Total expenditure in the year		3,715	3,666
Net income/(expenditure)for the financial year		4,413	1,046

The accounting policies and notes on pages 28 to 50 form part of these financial statements.

		Unrestricted	Restricted	Endowment	2019	2018
	Note	funds £'000	funds £'000	funds £'000	total £'000	total £'000
Fixed assets						
Investments	9	-	31,130	5,765	36,895	35,888
Intangible assets	10	191	-	-	191	81
		191	31,130	5,765	37,086	35,969
Current assets						
Debtors	11	534	1,512	200	2,246	2,212
Cash held in investment portfolio	9	3,234	13,148	-	16,382	17,077
Cash at bank and in hand		1,304	911	305	2,520	2,670
Total current assets		5,072	15,571	505	21,148	21,959
Liabilities						
Creditors: Amounts falling due within 1 year	12	(147)	(4,804)	(188)	(5,139)	(8,236)
Net current assets/(liabilities)		4,925	10,767	317	16,009	13,723
Creditors: Amounts falling due after more than 1 year	13	-	(3,204)	(213)	(3,417)	(4,225)
Total net assets		5,116	38,693	5,869	49,678	45,467
Funds	4.5					
Endowment Prostricted	16	-	-	5,869	5,869	6,071
Restricted	16 16	- 5,116	38,693	-	38,693 5,116	35,383 4,013
Unrestricted	16	J, 110		-	3,110	4,013
Total funds	16	5,116	38,693	5,869	49,678	45,467

The accounting policies and notes on pages 28 to 50 form part of these financial statements.

Full comparatives for the year ended 31 March 2018 are included at Note 19.

The financial statements were approved and authorised for issue by the Board of Directors on 11 July 2019 and were signed on its behalf by:

Mervyn Walker Chairman

my lah

11 July 2019

## Cashflow statement Year ended 31 March 2019

	Total funds	Total funds
	2019	2018
	£000	£000
Cash flows from operating activities		
Net cash (used in)/provided by operating activities	(1,204)	(273)
Cash flows from investing activities		
Dividends and interest from investments	288	277
Net movement of assets within investment portfolio	219	-
Proceeds from sale of long term investments	-	34,934
Development of fixed assets	(148)	(81)
Purchase of long term investments		(21,398)
Net cash provided by / (used in) investing activities	359	13,732
		10,702
Change in cash and cash equivalents in the reporting period	(845)	13,459
	(6.6)	10,100
Cash and cash equivalents at the beginning of the reporting	19,747	6,288
period  Cash and cash equivalents at the end of the accounting	<u> </u>	
period	18,902	19,747
Reconciliation of cash flows from operating activities		Total funds
Reconciliation of cash flows from operating activities	Total funds 2019	Total funds 2018
Reconciliation of cash flows from operating activities	Total funds	Total funds 2018 £000
Reconciliation of cash flows from operating activities  Net income/(expenditure) for the period as per SOFA	Total funds 2019	2018
Net income/(expenditure) for the period as per SOFA Adjustments for:	Total funds 2019 £000 4,211	2018 £000 1,604
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments	Total funds 2019 £000 4,211 (1,226)	2018 £000 1,604 (434)
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments  Dividends and interest from investments	Total funds 2019 £000 4,211 (1,226) (288)	2018 £000 1,604
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation	Total funds 2019 £000 4,211 (1,226) (288) 38	2018 £000 1,604 (434) (277)
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments  Dividends and interest from investments	Total funds 2019 £000 4,211 (1,226) (288)	2018 £000 1,604 (434)
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation     (Increase)/decrease in debtors	Total funds 2019 £000 4,211 (1,226) (288) 38 (34)	2018 £000 1,604 (434) (277) - (505)
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments Dividends and interest from investments Amortisation (Increase)/decrease in debtors Increase/(decrease) in creditors	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)	2018 £000 1,604 (434) (277) - (505) (661)
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments Dividends and interest from investments Amortisation (Increase)/decrease in debtors Increase/(decrease) in creditors	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)	2018 £000 1,604 (434) (277) - (505) (661)
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation     (Increase)/decrease in debtors     Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)	2018 £000 1,604 (434) (277) - (505) (661) (273)
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation     (Increase)/decrease in debtors     Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)  Total funds 2019	2018 £000 1,604 (434) (277) - (505) (661) (273) Total funds 2018
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation     (Increase)/decrease in debtors     Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)	2018 £000 1,604 (434) (277) - (505) (661) (273)
Net income/(expenditure) for the period as per SOFA  Adjustments for:     (Gains)/losses on investments     Dividends and interest from investments     Amortisation     (Increase)/decrease in debtors     Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)  Total funds 2019	2018 £000 1,604 (434) (277) - (505) (661) (273) Total funds 2018
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments Dividends and interest from investments Amortisation (Increase)/decrease in debtors Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities  Analysis of cash and cash equivalents	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)  Total funds 2019 £000	2018 £000 1,604 (434) (277) (505) (661) (273) Total funds 2018 £000
Net income/(expenditure) for the period as per SOFA  Adjustments for:  (Gains)/losses on investments Dividends and interest from investments Amortisation (Increase)/decrease in debtors Increase/(decrease) in creditors  Net cash (used in)/provided by operating activities  Analysis of cash and cash equivalents  Cash in hand	Total funds 2019 £000 4,211  (1,226) (288) 38 (34) (3,905)  (1,204)  Total funds 2019 £000 2,520	2018 £000 1,604 (434) (277) - (505) (661) (273) Total funds 2018 £000 2,670

## Notes to the financial statements Year ended 31 March 2019

#### 1 Accounting policies

#### a) Basis of preparation

The financial statements are prepared under the historical cost convention as modified to include the revaluation of investments at market value, and in accordance the Statement of Recommended Practice for Charities (SORP 2015) and applicable accounting standards (FRS 102). Moorfields Eye Charity meets the definition of a public benefit entity under FRS102.

The accounts are prepared in pounds sterling rounded to the nearest thousand.

At 31 December 2015, Special Trustees of Moorfields Eye Hospital ('The Special Trustees') became a linked charity of Moorfields Eye Charity.

#### b) Going concern

The Trustees consider that there are no material uncertainties regarding the charity's ability to continue as a going concern.

#### c) Critical accounting judgements and estimates

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of the charities accounting policies and the reported assets, liabilities, income and expenditure and the disclosures made in the financial statements. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Judgements have been made in respect of the valuation of legacy income accrued at the year end. These judgements are explained fully at (i) below.

#### d) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

#### e) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors are initially recognised at transaction value and subsequently measured at their settlement value.

#### f) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

## Notes to the financial statements (continued) Year ended 31 March 2019

#### 2 Accounting policies (continued)

#### g) Foreign currency translation

The Charity's functional and presentation currency is pounds sterling. Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are recognised in the Statement of Financial Activities

#### h) Income

Income is included in the Statement of Financial Activities as soon as all conditions for receipt have been met - including entitlement, probability of receipt and measurement of the amount.

#### i) Legacies

In line with our income policy, legacy income is accrued at the balance sheet date if it can be shown there is an entitlement to the funds, if there is probability of receipt and the amount can be fairly measured. Only where all three of these factors can be satisfied is an amount included for the year. Legacy notifications and receipts are reviewed up to the balance sheet date and the results are adjusted if the likely receipt is considered material and there is evidence that we were entitled to the income at the year end.

#### j) Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefit will be required in settlement and the amount of the obligation can be measured reliably.

#### k) Grants payable and reserves

Grants payable are recognised in the financial statements, on an accruals basis, when the charity has incurred a constructive or legal obligation to make a grant. The charity makes multi-year grants, often dependent on multi-year income pledges. This sometimes results in restricted funds being in deficit pending the receipt of pledged income. Grants payable in more than one year from the balance sheet date are shown at net present value.

The amount spent on grants in any year is related to the reserves policy of the Trustees, which seeks to maintain a maximum level of Unrestricted Funds. This allows the Charity to maintain its working capital, which provides a regular flow of investment income for grants in future periods. As required by FRS 102, long term liabilities have been discounted to present value as the impact of discounting is material.

#### I) Governance and Support Costs

This includes all expenditure, including salaries, relating to activities that are not directly related to fundraising or the management of grants and research.

## Notes to the financial statements (continued) Year ended 31 March 2019

#### 1 Accounting policies (continued)

#### m) Investments

Investments are shown at market value. Changes in value during the year, whether realised or unrealised, are included in the Statement of Financial Activities. Investment management costs are shown as a cost of generating funds.

#### n) Tangible fixed assets and depreciation

Assets costing more than £5,000 are capitalised. Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment.

Depreciation is provided at rates calculated to write off the cost of the assets, less any residual value, over their expected useful lives.

#### o) Intangible fixed assets and amortisation

Intangible fixed assets are carried at cost, net of amortisation and any provision for impairment.

Amortisation is provided at rates calculated to write off the cost of the assets, less any residual value, over their expected useful lives. The intangible assets of the charity are the costs of developing the grants management and fundraising database and software. These are amortised over the period of the initial licence period, four years.

## p) Assets in the course of construction or development

Where tangible or intangible assets are in the course of construction or development at the year end, the costs incurred to the balance sheet date are shown as fixed assets.

#### q) Fund structure and objects

All funds are used for the main Objects of the Charity. The main categories of funds are:

- Restricted trusts created by donors with specific objects or linked charities;
- Expendable Endowment incoming resources that were received by the Special Trustees in excess of £500k and which they did not expect to spend in one year;
- Unrestricted resources that can be used by the Trustees at their discretion; and
- Designated unrestricted funds for which the Trustees have set a specific purpose.

#### r) General information

Moorfields Eye Charity is a company registered in England and Wales (company number 7543237). Its registered address is set out on page 2. Its objects are set out on page 3.

## Notes to the financial statements (continued) Year ended 31 March 2019

2 Income and end	owments from								
		Unrestricted	Restricted	<b>Endowment</b>	2019	Unrestricted	Restricted	Endowment	2018
		funds	funds	funds	total	funds	funds	funds	tota
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Donations									
Individual givin	g	497	183	-	680	607	114	-	721
Major gifts		155	2,605	-	2,760	71	1,660	-	1,731
Legacies		1,061	1,922	61	3,044	705	769	302	1,776
Events		127	128		255	189	114	-	303
Raffles and lotter	у	57	-	-	57	63	-	-	63
		1,897	4,838	61	6,796	1,635	2,657	302	4,594
Investment portfo	olio	25	201	59	285	50	161	66	277
Interest on bank		3	-	-	3	-	-	-	-
		1,925	5,039	120	7,084	1,685	2,818	368	4,871
3 Expenditure on	raising funds								
		Unrestricted	Restricted	Endowment	2019	Unrestricted	Restricted	Endowment	2018
		funds	funds	funds	Total	funds	funds	funds	total
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Fundraising cos	ats	265	170	_	435	333	160	_	493
Fundraising sta		247	335	-	582	235	250	-	485
Support costs (I		33	-	-	33	7	-	-	7
		545	505	-	1,050	575	410	-	985
Investment mar	nagement costs	25	119	56	200	3	98	27	128
		570	624	56	1,250	578	508	27	1,113

## Notes to the financial statements (continued) Year ended 31 March 2019

4	Charitable activities	Grant commitments £'000	Direct costs £'000	Support costs £'000	2019 total £'000	Grant commitments £'000	Direct costs £'000	Support costs £'000	2018 total £'000
	Charitable activities								
	Research	1,655	-	-	1,655	816	-	-	816
	Equipment	213	-	-	213	874	-	-	874
	Patient and staff welfare	194	-	-	194	90	-	-	90
	Education	191	-	-	191	70	-	-	70
	Grant commitments	2,253	-	-	2,253	1,850	-	-	1,850
	Capital project	-	16	-	16	-	68	-	68
	Grants management – staff costs (note 6)	-	107	-	107	-	93	-	93
	Grants management - other costs	-	4	-	4	-	3	-	3
	Governance and support (Note 5)	-	5	464	469	-	-	574	574
	•	2,253	132	464	2,849	1,850	164	574	2,588

Grant commitments are net of commitments unused and released in the year as well as net present value adjustments for the current and prior year. More details are shown in Note 14.

## Notes to the financial statements (continued) Year ended 31 March 2019

Governance and support costs	Fundraising costs	Charitable activities	2019 total	Fundraising costs	Charitable activities	2018 total
Governance	£'000s	£'000s	£'000s	£'000s	£'000s	£'000s
Audit fees	-	13	13	-	16	16
Insurance (incl. indemnity insurance)	-	3	3	-	3	3
Trustee expenditure	-	5	5	-	2	2
Other governance Costs		15	15	7	28	35
Total governance Costs	-	36	36	7	49	56
Support Costs						
Cost of staff employed by the Charity (note 6)	-	398	398	-	421	421
Amortisation	33	5	38	-	-	-
Other support costs		30	30	-	104	104
Total support costs	33	433	466	-	525	525
Total governance and support costs (note 4)	33	469	502	7	574	581

Other governance costs include legal fees and the cost of electronic board papers.

Other support costs include IT costs and recruitment costs.

The cost of time spent by governance and support staff on fundraising is allocated to the cost of raising funds based on an assessment of time spent on that activity.

The remaining governance and support costs are allocated to the Charity's funds pro rata to the closing balances of individual funds. Where it is not legally possible to charge overheads to restricted funds, or the closing balances of funds are less than £100,000, no allocation is made. As grant commitments are the Charity's main charitable activity, governance and support costs have not been allocated to grant commitments but are shown separately in the Statement of Financial Activities.

## Notes to the financial statements (continued) Year ended 31 March 2019

\_\_\_\_\_

#### 6 Staff costs

The total cost for the year was £1,086,699 (2018: £999,230) made up as follows:

			Governance				Governance	
	<b>Fundraising</b>	Grants	and support	2019 total	Fundraising	Grants	and support	2018 total
	£000	£000	£000	£000	£000	£000	£000	£000
Salary cost	480	88	317	885	352	77	242	671
Employer NI	49	10	36	95	41	8	27	76
Pension Contributions	40	9	22	71	38	8	24	70
Cost of staff employed by the Charity	569	107	375	1,051	431	93	293	817
Cost of services provided by Moorfields and other suppliers	13	-	23	36	54	-	128	182
	582	107	398	1,087	485	93	421	999

#### Staff numbers

otali mambero	Average FTE for year	Average for year	As at 31 March 2019	Average FTE for year	Average for year	As at 31 March 2018
Staff employed by the Charity Staff provided by Moorfields and other suppliers	20 1	22 1	23 0	15 3	17 5	17 5
	21	23	23	18	22	22

On 1 April 2017 the staff formerly employed by Moorfields to provide fundraising and grants management services were transferred to the Charity under the TUPE regulations.

## Notes to the financial statements (continued) Year ended 31 March 2019

#### 6 Staff costs (continued)

#### Salary bandings

The number of employees of the Charity receiving emoluments of more than £60,000 (excluding employer pension costs) during the year were as follows:

Banding	2019	2018
£70,001 - £80,000	2	1
£100,001 - £110,000	1	1

#### **Key management Personnel**

The key management personnel during the year were the Trustees and the Management Group. The Trustees received no remuneration for their positions. The Management Group is made up of the Chief Executive, the Director of Development, the Director of Grants and Research, and the Director of Finance and Resources. All of the Management Group are employed by the Charity.

The total cost to the charity of all people who performed the work of the Management Group during the year, including those employed under agency agreements, was £350,686 (2018: £391,372).

#### 7 Pensions

The Charity participates in the NHS pension scheme for those staff that transferred to the Charity from employment with Moorfields. It is not possible to separately identify the assets of the scheme relating to the Charity. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £40,532 (2018: £52,067). Contributions totalling £3,207 were payable to the fund at the balance sheet date and are included in creditors. The Charity pays the standard rate of contribution to the scheme and no historic deficits are being funded through additional contributions.

The Charity participates in the People's Pension, ensuring all staff are able to participate in an auto-enrolment pension scheme. The scheme is a defined contribution scheme where the assets are held separately from the Charity in an independently managed fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £29,752 (2018: £17,701). Contributions totalling £3,996 were payable to the fund at the balance sheet date and are included in creditors. Employees make contributions matched by the Charity at 4% or 8% of salary.

#### 8 Taxation

No tax charge has arisen in the year as the registered charity falls within Chapter 3 of the Corporation Taxes Act 2010 and section 256 of the Taxation of Chargeable Gains Act 1992, and is therefore potentially exempt from taxation of income and gains to the extent that they are applied to its charitable purposes. The Charity is not registered for VAT. Expenditure is shown inclusive of VAT.

#### Notes to the financial statements (continued) Year ended 31 March 2019

#### 9 Fixed asset investments

	2019 total	2018 total
Common investment funds	£'000	£'000
Market value at 1 April	52,965	50,132
Net (withdrawals)/investments	(1,000)	2,250
Income and distributions	286	277
Management fees	(200)	(128)
Net movements in valuation	1,226	434
Market value at 31 March	53,277	52,965
Cash held as part of the investment portfolio	(16,382)	(17,077)
Total investments at 31 March	36,895	35,888

#### Withdrawals / further investment

During the year the Trustees withdrew £1,000k from cash investments for operational requirements (2018: invested £2,250k)

#### Historic cost of investment

The original investment portfolio was acquired by the Charity as part of the merger with the former Special Trustees of Moorfields on 31 December 2015. At 31 December 2015, the date of the merger, the value of the portfolio was £41,401k, being investments of £40,908k and cash of £493k.

### Notes to the financial statements (continued) Year ended 31 March 2019

#### 10 Fixed assets – intangible assets

	Software £'000	Assets in development £'000	2019 total £'000	Software £'000	Assets in development £'000	2018 total £'000
Cost						
At 1 April	-	81	81	-	81	81
Additions	-	148	148	-	-	-
Transfers	229	(229)	-	-	-	-
At 31 March	229	-	229	-	81	81
Amortisation						
At 1 April	-	-	-	-	-	-
Charge for the year	(38)	-	(38)	-	-	-
At 31 March	(38)		(38)	-	-	-
Net book value at 31 March	191	-	191		81	81

Intangible assets are represented by our customer relationship management system developed over the period January 2018 to July 2018. Amortisation has been charged from August 2018 when the fundraising functionality of the system became operational. Additions from that date relate to the development of our grants management module of the system which became operational at the start of the new financial year.

Intangible assets are funded from unrestricted funds. Amortisation is treated as unrestricted expenditure.

## Notes to the financial statements (continued) Year ended 31 March 2019

11	Debtors	Unrestricted	Restricted	Endowment	2019	Unrestricted	Restricted	Endowment	2018
		funds £'000	funds £'000	funds £'000	total £'000	funds £'000	funds £'000	funds £'000	total £'000
	HMRC Gift Aid accrual Other debtors Accrued income Prepayments	14 1 476 43	26 25 1,461	- - 200	40 26 2,137 43	85 - 578 3	55 50 1,139	- - 302 -	140 50 2,019 3
		534	1,512	200	2,246	666	1,244	302	2,212

# 12 Creditors: amounts falling due within one year

	Unrestricted funds £'000	Restricted funds £'000	Endowment funds £'000	2019 total £'000	Unrestricted funds £'000	Restricted funds £'000	Endowment funds £'000	2018 total £'000
Grants payable (note 14) Other creditors	43 104	4,656 148	187 1	4,886 253	- 391	5,230 2,472	95 48	5,325 2,911
	147	4,804	188	5,139	391	7,702	143	8,236

# 13 Creditors: amounts falling due after one year

	Unrestricted funds £'000	Restricted funds £'000	Endowment funds £'000	2019 total £'000	Unrestricted funds £'000	Restricted funds £'000	Endowment funds £'000	2018 total £'000
Grants payable (note 14)	-	3,204	213	3,417	-	4,164	61	4,225

#### Notes to the financial statements (continued) Year ended 31 March 2019

14	Grants payable	Unrestricted	Restricted	Endowment	2019	Unrestricted	Restricted	Endowment	2018
		funds £'000	funds £'000	funds £'000	total £'000	funds £'000	funds £'000	funds £'000	total £'000
	Grant commitments at start of year	-	9,394	156	9,550	54	12,282	242	12,578
	NPV adjustment prior year	-	513	7	520	-	415	13	428
	Grant commitments made during the year Grant commitments	185	2,303	290	2,778	-	2,432	-	2,432
	released in year	-	(757)	-	(757)	-	(490)	-	(490)
	Grant commitments paid in year	(142)	(3,322)	(36)	(3,500)	(54)	(4,732)	(92)	(4,878)
	Grant commitments	43	8,131	417	8,591	-	9,907	163	10,070
	NPV adjustment current year	-	(271)	(17)	(288)	-	(513)	(7)	(520)
	Grant commitments at end of year	43	7,860	400	8,303	-	9,394	156	9,550
	Within one year (note 12)	43	4,656	187	4,886	-	5,230	95	5,325
	After more than one year (note 13)	-	3,204	213	3,417	-	4,164	61	4,225
	Grant commitments at end of year	43	7,860	400	8,303	-	9,394	156	9,550

Grant commitments are all made to Moorfields or University College London (UCL). Grants to UCL relate mainly for work by the UCL Institute of Ophthalmology. Details of grants made in the year are set out in the Trustees' Annual Report.

#### 15 Commitments

The Trustees have committed £10,000,000 from the funds of the former Special Trustees towards the cost of the land for Oriel, the new hospital, education and research facility. This is expected to be required in March 2021. To ensure there is limited risk of the funds reducing in value, this money has been removed from the long term investment portfolio and is being held as a short term investment cash deposit.

At 31 March 2018 the Trustees had entered into a contract for the development of a new customer relationship management system. At 31 March 2018, the project had incurred expenditure of £81,128, which was shown as an asset under construction. The project was completed in 2019 and there was no remaining commitment at 31 March 2019. The asset is shown in Fixed assets: intangible assets.

#### Notes to the financial statements (continued) Year ended 31 March 2019

16 Funds

Total Funds Summary (current year):		Balance 1 April 2018	Income	Expenditure	Transfers between funds	Gains and losses	Balance 31 March 2019
		£'000	£'000	£'000	£'000	£'000	£'000
Restricted funds	16a	2,442	3,014	(1,404)	(1)	-	4,051
Linked Charities	16b	32,941	2,025	(1,462)	1	1,137	34,642
Total restricted funds		35,383	5,039	(2,866)	-	1,137	38,693
Endowed funds	16c	6,071	120	(384)	-	62	5,869
Unrestricted funds	16d 	4,013	1,925	(849)	-	27	5,116
Total Funds		45,467	7,025	(4,099)	-	1,226	49,678

Total Funds Summary (prior year):		Balance 1 April 2017	Income	Expenditure	Transfers between funds	Gains and losses	Balance 31 March 2018
		£'000	£'000	£'000	£'000	£'000	£'000
Restricted funds	16a	1,323	1,900	(846)	-	65	2,442
Linked Charities	16b	33,456	918	(1,603)	1	169	32,941
Total restricted funds		34,779	2,818	(2,449)	1	234	35,383
Endowed funds	16c	5,513	368	(35)	-	225	6,071
Unrestricted funds	16d	3,571	1,685	(1,217)	(1)	(25)	4,013
Total Funds		43,863	4,871	(3,701)	-	434	45,467

#### **Funds in deficit**

The Charity enters multi-year gift agreements with donors to fund projects or equipment but accounting rules prevent the Charity from accruing the future income. Multi-year grant awards are also made and accounting rules require the long-term liability to be recognised fully on award. This can have the effect of creating funds in deficit. At 31 March 2019 there were seven funds in deficit (2018: nine funds) amounting to £542k (2018: £1,470k). The Trustees are satisfied that sufficient funds will be raised in future accounting periods to reverse the deficit in full.

## Notes to the financial statements (continued) Year ended 31 March 2019

#### 16a Restricted funds

Buildings	Balance 1 April 2018 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2019 £'000
Oriel capital	636	31	(16)	-	-	651
Other building funds	31	-	-	-	-	31
Equipment	110	2	(28)	-	-	84
Patient welfare	19	61	(94)	-	-	(14)
Research						
General research	2,041	383	(213)	(7)	-	2,204
London project	(1,108)	1,192	(369)	-	-	(285)
Other research funds	713	1,345	(684)	6	-	1,380
Total Funds	2,442	3,014	(1,404)	(1)	-	4,051

Buildings	Balance 1 April 2017 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2018 £'000
Oriel capital Other building funds	691 30	2 1	(68)	-	11 -	636 31
Equipment	157	114	(170)		9	110
Patient welfare	17	-	2	-	-	19
Research						
General research	1,923	261	(173)	3	27	2,041
London project	(1,716)	760	(153)	-	1	(1,108)
Other research funds	221	762	(284)	(3)	17	713
Total Funds	1,323	1,900	(846)	-	65	2,442

# Notes to the financial statements (continued) Year ended 31 March 2019

## 16a Restricted funds (continued)

The restricted funds held are explained below:

Building	
General Building Fund	Restricted donations given for the maintenance and repair of the Moorfields Estate.
RDCEC Building	Restricted donations given for the maintenance and repair of the Richard Desmond Children's Eye Centre.
Oriel Capital	Restricted donations given for Moorfields' long-term redevelopment project.
Equipment	
General Equipment	Restricted donations given for the purchase of specialist equipment for either research or clinical services.
Summer 2014 Equipment Appeal	Restricted donations to replace a broken stem cell incubator at Moorfields; any surplus donations will be used to support stem cell therapy research.
Patient Welfare	
RDCEC Non Research	Restricted donations given for the work carried out in the Richard Desmond Children's Eye Centre.
General Patient Care	Restricted donations given for the general welfare of Moorfields' patients.
Prof Khaw	Restricted donation given for Prof Khaw to support those with glaucoma who may struggle to access the relevant care they require.
Research	
General Research	Restricted donations given for research purposes.
Adnexal Research	Restricted donations given for research into the causes and treatment of diseases involving tissues surrounding the eye ball, including the eyelids, extra-ocular muscles, socket and tear system.
AMD Research	Restricted donations given for research into the causes and treatment of Age-Related macular degeneration.
Aniridia Research	Restricted donations given for research into the causes and treatment of Aniridia.
Cataract Research	Restricted donations given for research into the causes and treatment of Cataracts.
Corneal Research	Restricted donations given for research into the causes and treatment of diseases of or involving the cornea.
Diabetes Related Research	Restricted donations given for research into the causes and treatment of eye disease linked to diabetes.
Eye Cancer Research	Restricted donations given for research into the causes and treatment of ocular cancers.
Gene Therapy Research	Restricted donations given for research into using or developing Gene Therapy for eye diseases.
Genetic Research	Restricted donations given for research into the genetic background to eye disease.
Glaucoma Research	Restricted donations given for research into the causes and treatment of glaucoma.
John Dart Research	Restricted donations given for research led by Professor John Dart and his team.

## Notes to the financial statements (continued) Year ended 31 March 2019

## 16a Restricted funds (continued)

Research (continued)	
London Project	Restricted donations given for research related to the London Project which aims to use Stem Cell technology to restore sight, prevent progression and ultimately improve the quality of life for patients with Age-Related Macular Degeneration (AMD) and other retinal and macular disorders, led by Prof Pete Coffey and Mr Lyndon da Cruz and their teams.
Macular Degeneration	Restricted donations given for research into the causes and treatment of macular degeneration.
Ocular Prosthetics	Restricted donations given to support the development of and research into ocular prosthetics.
Ocular repair/regeneration	Restricted donations given for research into ocular repair and regeneration mechanisms and treatments.
Paediatric Research	Restricted donations given for research into the causes and treatment of eye conditions in children.
Project Oriel Research	Restricted donations for specific research projects as part of the £25m research goal within the £100m MEH redevelopment fundraising campaign.
Retinal Research	Restricted donations given for research into the causes and treatment of retinal diseases.
RP and Usher Syndrome	Restricted donations given for research into the causes and treatment of retinitis pigmentosa and Usher syndrome.
Stargardt Research	Restricted donations given for research into the causes and treatment of Stargardt disease.
Stem Cell Research	Restricted donations given for research into utilising Stem Cells in the treatment of eye disease.
Uveitis Research	Restricted donations given for research into the causes and treatment of uveitis.
V R Research	Restricted donations given for research into the causes and treatment of vitreo retinal conditions.
DF-AMD Research	Restricted donations given for research into the causes and treatment of age-related macular degeneration.
Sir Jules Thorn Unit	Restricted donations given in support of the development of and research carried out in the Sir Jules Thorn Unit.
UNITE	Restricted donations given for research related to the UNITE international consortium which aims to advance the education of and research into ocular inflammation and immune-mediated disease of the eye.
Satellite Sites	Restricted donations given for use by Moorfields operational teams at other hospitals.
St. Georges Satellite	
Bedford Satellite	
Ealing Satellite	

## Notes to the financial statements (continued) Year ended 31 March 2019

#### 16b Restricted Funds – linked charities

	Balance 1 April 2018	Income	Expenditure	Transfers between funds	Gains and losses	Balance 31 March 2019
	£'000	£'000	£'000	£'000	£'000	£'000
Special purpose	133	1	(44)	-	-	90
Patient welfare	26	-	-	-	-	26
Staff welfare and amenities	211	-	(45)	-	-	166
Research				-	-	
General research	578	368	(423)	-	-	523
Former special trustees	31,794	1,655	(921)	-	1,137	33,665
Other research funds	199	1	(29)	1	-	172
Total Funds	32,941	2,025	(1,462)	1	1,137	34,642

	Balance 1 April 2017 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses	Balance 31 March 2018 £'000
Special purpose	83	1	41	-	8	133
Patient welfare	25	-	-	-	1	26
Staff welfare and amenities	231	-	(23)	-	3	211
Research General research Former special trustees Other research funds	1,411 31,440 266	262 647 8	(1,135) (393) (93)	1 - -	39 100 18	578 31,794 199
Total Funds	33,456	918	(1,603)	1	169	32,941

#### **Linked charities**

Under a Linking Directive from the Charity Commission, following the merger at 31 December 2015, the former Special Trustees of Moorfields Eye Hospital and its linked charities become Linked Charities of the Charity. The objects of the former Special Trustees meant the unrestricted funds of that charity became restricted funds within Moorfields Eye Charity.

## Notes to the financial statements (continued) Year ended 31 March 2019

## 16b Restricted funds – linked charities (continued)

The restricted funds held are explained below:

Destricted	
Restricted	
Children's Centre	
/Paediatric Research	Restricted donations given for research into and treatment of children's eye conditions.
Arthur Luck Oncology/Eye	
Cancer	A fund created from a single donation for research into tumours in any part of the visual system.
Francis and Renee Hock	A fund created from a single donation to further the research into the treatment of medical and surgical conditions of the vitreous
Fund	and retina.
Restricted - Special Purpos	se
Patient Welfare	
Chapel Fund (Helen	
Brooker)	Funds held for the maintenance and refurbishment of the Multi-Faith Centre.
Research	
General Research	Restricted donations given for research purposes.
Optical Department	Restricted donations given for use by the optical department.
Research Scholarship Fund	Restricted donations given to create a scholarship fund for the publication of research.
Glaucoma Research	Restricted donations given for research into the treatment and cure of glaucoma.
Retinal Research	Restricted donations given for research into retinal conditions.
Former Special Trustees	The former Unrestricted Fund of Special Trustees whose funds were restricted for use wholly or mainly in support of Moorfields.
Staff Welfare and	
Amenities	
Nurses	Restricted donations given for general improvements for the comfort of nursing staff.
Retinal Diagnostic	
Education Fund	Restricted donations given for educational purposes for full-time medical members of the retinal diagnostic department.
	Restricted donations given for the relief of those staff facing hardship and to assist with removal, temporary housing, childcare,
Staff Benevolent Fund	set-up costs and language training especially for overseas staff but otherwise staff generally.

## Notes to the financial statements (continued) Year ended 31 March 2019

16c Endowment funds

	Balance 1 April 2018 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2019 £'000
General endowment funds	5,092	120	(104)	-	62	5,170
Other endowment funds	979	-	(280)	-	-	699
Total Funds	6,071	120	(384)	-	62	5,869
	Balance 1 April 2017 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2018 £'000
General endowment funds Other endowment funds	4,546 967	366 2	(27) (8)	-	207 18	5,092 979
Total Funds	5,513	368	(35)	-	225	6,071

Endowment Funds:	
Samaritan Endowment Funds	Restricted funds given to relieve in cases of need persons leaving Moorfields Eye Hospital in such ways conducive to their recovery or betterment.
Children's Endowment	
Funds	An endowment fund formerly part of the Samaritan Fund on which income is used for the specific welfare of child patients.
James and Edmonds	An endowment fund formerly part of the Samaritan Fund on which income earned is used for the purposes of the Samaritan
Funds	Fund.
Children's Ophthalmic Fund	Income is used for the specific welfare of child patients.
General Endowment Fund	General donations in excess of £0.5million received in one year; for expenditure over a number of years.
Sutor Research Fund	An expendable endowment fund created by a legacy for research excluding the use of animals.

## Notes to the financial statements (continued) Year ended 31 March 2019

16d General unrestricted funds

Unrestricted funds:	Balance 1 April 2018 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2019 £'000
General/Unrestricted	3,513	1,925	(849)	-	27	4,616
Designated Capital Fund	500	-	-	-	-	500
Total Unrestricted Funds	4,013	1,925	(849)	-	27	5,116

Unrestricted funds:	Balance 1 April 2017 £'000	Income £'000	Expenditure £'000	Transfers between funds £'000	Gains and losses £'000	Balance 31 March 2018 £'000
General/Unrestricted	3,071	1,685	(1,217)	(1)	(25)	3,513
Designated Capital Fund	500	-		-		500
Total Unrestricted Funds	3,571	1,685	(1,217)	(1)	(25)	4,013

Unrestricted Funds:	
General/Unrestricted	Resources that can be used by the Trustees at their discretion
Designated Capital Fund	Funds designated by the Trustees for Moorfields' long-term redevelopment project

#### Notes to the financial statements (continued) Year ended 31 March 2019

#### 17 Transactions with directors and connected persons

David Probert and Nick Strouthidis are directors of Moorfields Eye Hospital NHS Foundation Trust ('Moorfields'), as was Declan Flanagan. Johanna Moss is an associate director of that trust. Robert Jones is the vice chair of the membership council of that trust.

Dr Spence-Jones is a trustee of the Friends of Moorfields Eye Hospital (charity registration number 1161546).

Vicky Hastings is a member of the board of JP Morgan Asset Management (UK) Ltd and JP Morgan Asset Management International Ltd, both companies being related to our investment managers JP Morgan International Bank Ltd.

None of the Trustees received any remuneration during the year (2018: £Nil). Four Trustees (2018: two) were reimbursed for their travel and other related expenses totalling £2,485 (2018: £1,945).

None of the Trustees or members of key management staff of Moorfields or parties related to them has undertaken any material transactions with the Charity or with connected persons during the year.

During the year the Charity received human resources, facilities management and information systems services from Moorfields. These services were provided on an arms-length basis.

The Charity makes grants to Moorfields as set out in Note 14 above and explained further in the Trustees Report.

#### Notes to the financial statements (continued) Year ended 31 March 2019

Comparatives: statement of financial activities Unrestricted Restricted Endowment 2018 2017 funds funds funds total total £'000 £'000 £'000 £'000 £'000 Note Income and endowments from: 2 **Donations** 678 1,774 2,452 2,992 Legacies 2 705 302 1,776 3,257 769 **Events** 2 318 189 114 303 Other trading activities: 2 Raffles and lottery 63 63 76 2 50 161 66 277 276 Investment income **Total income** 2 1,685 2,818 368 4,871 6,919 **Expenditure on:** Raising funds: Fundraising 3 575 410 985 1,078 27 128 98 138 3 Investment management 3 27 3 578 508 1,113 1,216 Charitable activities: 4 Capital grants 200 Research 7 809 816 6,360 Equipment 66 874 785 808 Patient and staff welfare 90 90 135 Education 70 70 155 Capital project 68 68 Grants management 96 96 66 Governance and Support Costs 573 1 574 327 5 2,588 639 1,941 8 8,028 35 3,701 **Total expenditure** 1,217 2,449 9,244 Net income/(expenditure) before investment gains and losses 468 369 333 1,170 (2,325)Net gains/(losses) on 9 (25)234 225 434 2,699 investments Net income/(expenditure) 443 603 558 1,604 374 (1) 1 Transfers between funds Net movement in funds 442 604 558 1,604 374 Reconciliation of funds: Total funds brought forward 43,863 3,571 34,779 5,513 43,489 Total funds carried forward 4,013 35,383 6,071 45,467 16 43,863

# Notes to the financial statements (continued) Year ended 31 March 2019

## 19 Comparatives: Balance Sheet as at 31 March 2018

	Note	Unrestricted Funds £'000	Restricted Funds £'000	Endowment Funds £'000	2018 Total £'000	2017 Total £'000
Fixed assets			00.040			40.000
Investments Assets in the course of	9	-	29,940	5,948	35,888	48,990
development;	10	81	-	-	81	
		81	29,940	5,948	35,969	48,990
Current assets						
Debtors	11	666	1,244	302	2,212	1,707
Cash held in investment portfolio	9	2,636	14,441	-	17,077	1,142
Cash at bank and in hand		1,021	1,624	25	2,670	5,146
Total current assets		4,323	17,309	327	21,959	7,995
<b>Liabilities</b> Creditors: Amounts falling due within 1 year	12	(391)	(7,702)	(143)	(8,236)	(6,318)
Net current assets/(liabilities)		3,932	9,607	184	13,723	1,677
Creditors: Amounts falling due after more than 1 year	13	-	(4,164)	(61)	(4,225)	(6,804)
Total net assets		4,013	35,383	6,071	45,467	43,863
		,,,,,,	1	- ,	-,	
Funds						
Endowment	16	-	-	6,071	6,071	5,513
Restricted	16	-	35,383	-	35,383	34,779
Unrestricted	16	4,013	-	-	4,013	3,571
Total funds	16	4,013	35,383	6,071	45,467	43,863